Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por

Valproate Risk Minimization Material - Guide for Health Care Professionals

PATIENT CARD FOR VALPROATE: CONTRACEPTION AND PREGNANCY

Valproate Risk Minimization Material - Patient Card

Valproate Risk Minimization Material - Patient Guide

Dự Phòng Thuyên Tắc Huyết Khối Tĩnh Mạch Trên Bệnh Nhân Chấn Thương Nặng, Đa Chấn Thương Theo Hướng Dẫn Điều Trị Của Bộ Y Tế 2023

BR1DGE Symposium at EASD 2024

At the BR1DGE symposium at EASD 2024, leading experts shared new insights on early-stage (Stage 1 and 2) autoimmune type 1 diabetes (T1D), emphasizing the importance of screening for islet antibodies (IAbs) together with monitoring and education. Early type 1 diabetes identification can help to prepare people for a life with T1D.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Impacto de Rinitis Alérgica y Urticaria en Calidad de Vida

Advances in the biology of chronic GVHD

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Advances in the biology of chronic GVHD

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

MAT-CO-2400825 V1.0 03/2024

Page menu

Actualización normativa

Valproate Risk Minimization Material - Guide for Health Care Professionals

Valproate Risk Minimization Material - Patient Card

Valproate Risk Minimization Material - Patient Guide

Dự Phòng Thuyên Tắc Huyết Khối Tĩnh Mạch Trên Bệnh Nhân Chấn Thương Nặng, Đa Chấn Thương Theo Hướng Dẫn Điều Trị Của Bộ Y Tế 2023

BR1DGE Symposium at EASD 2024

Impacto de Rinitis Alérgica y Urticaria en Calidad de Vida

Advances in the biology of chronic GVHD

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study

Updated European Society of Blood and Marrow Transplantation consensus recommendations for GVHD prophylaxis and management in hematological malignancies after stem-cell transplantation

Advances in the biology of chronic GVHD

Clinical outcomes of cGvHD following allogeneic HSCT: A Swedish population-based real-world registry study